MINGYANG TECHNOLOGY
837663
Shanghai Weihong Electronic Technology
300508
Shenzhen Intellifusion Technologies
688343
4
Est Tools Co., Ltd.
300488
5
Jiangyin Pivot Automotive Products
301181
US Stock MarketDetailed Quotes
TERN Terns Pharmaceuticals
- 3.755
- +0.025+0.67%
Trading Feb 25 11:59 ET
318.95MMarket Cap-3.18P/E (TTM)
3.980High3.730Low358.73KVolume3.800Open3.730Pre Close1.37MTurnover0.70%Turnover RatioLossP/E (Static)84.94MShares11.40052wk High0.88P/B192.79MFloat Cap3.72052wk Low--Dividend TTM51.34MShs Float28.360Historical High--Div YieldTTM6.70%Amplitude1.450Historical Low3.832Avg Price1Lot Size
Terns Pharmaceuticals Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER...
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER...
131
5
6
$Terns Pharmaceuticals (TERN.US)$ Terns Pharmaceuticals Announces Positive Early Data From Phase 1 CARDINAL Trial of TERN-701 for Chronic Myeloid Leukemia
GlobeNewswire· 7 mins ago
Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels
Encouraging safety profile with no dose limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts
High leve...
GlobeNewswire· 7 mins ago
Compelling molecular responses starting at lowest dose level in heavily pre-treated patients with high baseline BCR-ABL transcript levels
Encouraging safety profile with no dose limiting toxicities, adverse event-related treatment discontinuations, or dose reductions across three dose escalation cohorts
High leve...
Brought it back down into the POC. If 6.47 holds could see it start curling but if shorts get control could see a push down towards 5.00
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
5
Back into the 240 day POC. Watch for the 7.33 level to form as a new base.
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
4
1
$Terns Pharmaceuticals (TERN.US)$
Terns Announces Proposed Public Offering
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $125 million in common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional $18.75 million of shares. Jefferies, TD Cowen, and UBS Investment Bank are acting as bookrunners for the offering.
Terns intends to...
Terns Announces Proposed Public Offering
Terns Pharmaceuticals (Nasdaq: TERN), a clinical-stage biopharmaceutical company, has announced a proposed public offering of $125 million in common stock and pre-funded warrants. The company plans to grant underwriters a 30-day option to purchase up to an additional $18.75 million of shares. Jefferies, TD Cowen, and UBS Investment Bank are acting as bookrunners for the offering.
Terns intends to...
1
$Terns Pharmaceuticals (TERN.US)$
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
Terns Pharmaceuticals (Nasdaq: TERN)announced positive Phase 1 clinical trial results for TERN-601, its once-daily oral GLP-1R agonist for obesity treatment. The trial showed:
- Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo-adjusted)
- Well-tolerated with no treatment-related dose ...
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
Terns Pharmaceuticals (Nasdaq: TERN)announced positive Phase 1 clinical trial results for TERN-601, its once-daily oral GLP-1R agonist for obesity treatment. The trial showed:
- Statistically significant mean weight loss up to 5.5% over 28 days (4.9% placebo-adjusted)
- Well-tolerated with no treatment-related dose ...
1
Finally over that 8.30 level that has been rejecting in the past. Here are the extended levels to watch.
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
Larger Image: tradingview.com...
$Terns Pharmaceuticals (TERN.US)$
1
$Terns Pharmaceuticals (TERN.US)$
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
Terns Pharmaceuticals announced new preclinical data supporting their compound TERN-501 in combination with a GLP-1 receptor agonist for treating obesity. The data was presented at the ADA’s 84th Annual Scientific Sessions. TERN-501, a highly selective THR-...
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
Terns Pharmaceuticals announced new preclinical data supporting their compound TERN-501 in combination with a GLP-1 receptor agonist for treating obesity. The data was presented at the ADA’s 84th Annual Scientific Sessions. TERN-501, a highly selective THR-...
2
1
No comment yet
Trending Stocks
Discussing
Tesla's earnings caused fluctuations, what's your market outlook？
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum
Moo Earnings
Jan 24 10:26
TSLA earnings preview: Grab rewards by guessing the opening price!
iluvpoptarts : ty much. I owe you a good joke when you're ready
manukahoney : when will CCTG pump occur? pre market today?
Jaguar8 OP manukahoney : it already started pumping Friday AH
manukahoney Jaguar8 OP : is it too late if i pump today during pre market sir?
Arrayfunction : This is probably an unknowable question - but logically, the massive cuts at NIH and NSF are going to stall out the biotech industry with what.....an 8-10 year lag? I know they don't tend to fund private clinical trials all that often, but they are shutting the tap off at the academic institutions that come up with the molecules that biotech/pharma buys the rights to?